Text this: Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

 _    _      ___     _    _      ___              
| || | ||   / _ \\  | \  / ||   / _ \\      ___   
| || | ||  | / \ || |  \/  ||  / //\ \\    /   || 
| \\_/ ||  | \_/ || | .  . || |  ___  ||  | [] || 
 \____//    \___//  |_|\/|_|| |_||  |_||   \__ || 
  `---`     `---`   `-`  `-`  `-`   `-`     -|_|| 
                                             `-`